Beneficient Q2 operating loss widens on deeper investment, financial instruments losses

By Reuters News


Overview

  • US alternative asset platform's fiscal Q2 revenue was negative, reflecting investment and financial instrument losses

  • Company posted a net loss attributable to common shareholders for the quarter

  • Operating expenses declined 6.9% yr/yr as management focused on cost reductions


Outlook

  • Company did not provide specific financial guidance for the current quarter or full year


Result Drivers

  • INVESTMENT AND FINANCIAL INSTRUMENT LOSSES - Co said negative revenue was mainly due to net investment losses and losses on financial instruments

  • COST REDUCTIONS - Operating expenses fell 6.9% yr/yr as management focused on efficiency and aligning costs with business activity

  • HIGHER CREDIT LOSSES AND ASSET SALES - Ben Liquidity segment's operating performance declined due to higher intersegment credit losses and asset sales


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

-$25.29 mln

Q2 Loss Per Share

$1.49


Analyst Coverage

  • Wall Street's median 12-month price target for Beneficient is $9.00, about 1,331.5% above its November 13 closing price of $0.63


Reuters Recommended Reads

  • Nov 16 - Enanta Pharmaceuticals misses Q4 revenue estimates, posts wider net loss

  • Nov 16 - GoPro Q3 revenue falls 41% on hardware decline

  • Nov 16 - Greenlane raises going-concern doubts; Q3 net revenue falls 91% as legacy business winds down


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.